{"id":19389,"date":"2021-11-04T09:13:34","date_gmt":"2021-11-04T08:13:34","guid":{"rendered":"https:\/\/idibell.cat\/?p=19389"},"modified":"2021-11-04T09:13:34","modified_gmt":"2021-11-04T08:13:34","slug":"les-cellules-del-cancer-de-mama-creen-escuts-de-collagen-per-protegir-se-del-sistema-immunitari","status":"publish","type":"post","link":"https:\/\/idibell.cat\/2021\/11\/les-cellules-del-cancer-de-mama-creen-escuts-de-collagen-per-protegir-se-del-sistema-immunitari\/","title":{"rendered":"Les c\u00e8l\u00b7lules del c\u00e0ncer de mama creen escuts de col\u00b7lagen per protegir-se del sistema immunitari"},"content":{"rendered":"

El nombre elevat de c\u00e8l\u00b7lules immunit\u00e0ries dins els tumors \u00e9s indicador de bon pron\u00f2stic, ja que aquestes ataquen al tumor i ajuden a destruir-lo. De quina manera les c\u00e8l\u00b7lules tumorals eviten l’entrada del sistema immunitari, com evitar-ho i el paper que hi juguen elements com la matriu extracel\u00b7lular, \u00e9s a dir, l’estructura molecular que sustenta les c\u00e8l\u00b7lules, encara s\u00f3n inc\u00f2gnites que no tenen una resposta clara.<\/p>\n

Ara, un estudi de la Universitat de George Washington, la Universitat de Texas, l’Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL<\/a>) i l’Institut Catal\u00e0 d’Oncologia (ICO<\/a>), publicat a la revista Nature<\/em><\/a>, acaba de descriure un mecanisme pel qual les c\u00e8l\u00b7lules tumorals mamaries generen escuts de matriu extracel\u00b7lular que eviten l’entrada de c\u00e8l\u00b7lules immunit\u00e0ries<\/strong>. A m\u00e9s, el treball proposa una nova estrat\u00e8gia terap\u00e8utica que evitaria la formaci\u00f3 d’aquests escuts.<\/p>\n

L’article, que ha comptat amb la participaci\u00f3 del grup de recerca en c\u00e0ncer de mama<\/a> de l’IDIBELL i de l’ICO liderat pel Dr. Miquel Angel Pujana<\/strong>, descriu que la prote\u00efna DDR1, present en la superf\u00edcie de les c\u00e8l\u00b7lules tumorals, s’uneix al col\u00b7lagen de la matriu i l’alinea formant un escut protector dels tumors enfront del sistema immunitari.<\/p>\n

A m\u00e9s, el treball suggereix l’\u00fas d’anticossos que bloquegen la formaci\u00f3 d’aquests escuts com a nova estrat\u00e8gia terap\u00e8utica<\/strong>. Els investigadors mostren que els anticossos espec\u00edfics que eviten la uni\u00f3 de la prote\u00efna DDR1 amb el col\u00b7lagen faciliten la destrucci\u00f3 dels tumors per part del sistema immunitari. El tractament amb aquests anticossos permet la infiltraci\u00f3 de c\u00e8l\u00b7lules immunit\u00e0ries i redueix aix\u00ed el creixement tumoral en assaigs precl\u00ednics amb ratolins.<\/p>\n

“\u00c9s la primera vegada que s’observa aquest mecanisme<\/em> \u201cd\u2019escut\u201d tumoral<\/em> -afirma el Dr. Pujana<\/strong>-, i, tot i que l\u2019estudi que s\u2019acaba de publicar es centra en c\u00e0ncer de mama, creiem que \u00e9s un mecanisme tamb\u00e9 utilitzat per altres tipus de c\u00e0ncer, el que significaria que el tractament amb anticossos espec\u00edfics podria ser \u00fatil terap\u00e8uticament en diferents escenaris<\/em>.”<\/p>\n

Aquest estudi s’ha centrat en models in vitro de tumors mamaris i diversos models de ratol\u00ed. En un futur pr\u00f2xim els investigadors esperen poder realitzar assajos cl\u00ednics en pacients de c\u00e0ncer de mama que ajudin a comprovar la seguretat del tractament amb anticossos espec\u00edfics i determinar-ne l’efic\u00e0cia.<\/p>\n

 <\/p>\n

 <\/p>\n

L\u2019Institut d’Investigaci\u00f3 Biom\u00e8dica de Bellvitge (IDIBELL) \u00e9s un centre de recerca en biomedicina creat l\u2019any 2004. Est\u00e0 participat per l’Hospital Universitari de Bellvitge i l\u2019Hospital de Viladecans de l’Institut Catal\u00e0 de la Salut, l’Institut Catal\u00e0 d’Oncologia, la Universitat de Barcelona i l\u2019Ajuntament de l\u2019Hospitalet de Llobregat.<\/em><\/p>\n

L\u2019IDIBELL \u00e9s membre del Campus d’Excel\u00b7l\u00e8ncia Internacional de la Universitat de Barcelona HUBc i forma part de la instituci\u00f3 CERCA de la Generalitat de Catalunya. L’any 2009 es va convertir en un dels cinc primers centres d\u2019investigaci\u00f3 espanyols acreditats com a institut d\u2019investigaci\u00f3 sanit\u00e0ria per l\u2019Instituto de Salud Carlos III. A m\u00e9s, forma part del programa \u201cHR Excellence in Research\u201d de la Uni\u00f3 Europea i \u00e9s membre de EATRIS i REGIC. Des de l\u2019any 2018, l\u2019IDIBELL \u00e9s un Centro Acreditado de la Fundaci\u00f3n Cient\u00edfica AECC (FCAECC).<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"

Un estudi publicat a Nature amb la participaci\u00f3 d\u2019IDIBELL i ICO demostra que una prote\u00efna de la superf\u00edcie de les c\u00e8l\u00b7lules tumorals mam\u00e0ries s\u2019uneix al col\u00b7lagen extracel\u00b7lular i l\u2019alinea per bloquejar l\u2019entrada de c\u00e8l\u00b7lules immunit\u00e0ries.<\/p>\n","protected":false},"author":8,"featured_media":19390,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"default","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"default","adv-header-id-meta":"","stick-header-meta":"default","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-opacity":"","overlay-gradient":""}},"footnotes":""},"categories":[332,390,447,452],"tags":[],"class_list":["post-19389","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-cancer","category-cancer-de-mama","category-p-de-mecanismes-molelculars-i-terapia-experimental-en-oncologia-oncobell","category-procure"],"publishpress_future_action":{"enabled":false,"date":"2024-11-28 22:34:04","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category"},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19389","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/comments?post=19389"}],"version-history":[{"count":1,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19389\/revisions"}],"predecessor-version":[{"id":19391,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/posts\/19389\/revisions\/19391"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media\/19390"}],"wp:attachment":[{"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/media?parent=19389"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/categories?post=19389"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/idibell.cat\/wp-json\/wp\/v2\/tags?post=19389"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}